This study provides a piece of preliminary evidence that GSMs-TACE has the potential to be used in combination with immune adjuvant therapies such as therapies targeting PD-1 or PDL-1 to increase the efficacy of HCC treatment. The gene discussed is CD274; the disease is hepatocellular carcinoma.